IQVIA Holdings Inc. has recently released its 10-Q report, providing a comprehensive overview of its financial condition and results of operations. The company is a leading global provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
In the 10-Q report, IQVIA highlights its commitment to using artificial intelligence ("AI") responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance, and patient safety. The company also emphasizes its dedication to accelerating the development and commercialization of innovative medical treatments to improve patient outcomes and population health worldwide. With approximately 90,000 employees in over 100 countries, IQVIA is a global leader in protecting individual patient privacy and providing insights and execution capabilities to various healthcare stakeholders.
In terms of financial performance, IQVIA reported total revenues of $4.017 billion for the second quarter of 2025, representing a 5.3% increase compared to the same period in 2024. For the first six months of 2025, the company's revenues increased by 3.9% to $7.846 billion compared to the same period in 2024. The growth in revenues was primarily driven by constant currency revenue growth in all three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Cost of revenues, exclusive of depreciation and amortization, increased by $206 million for the three months ended June 30, 2025, and by $293 million for the six months ended June 30, 2025, compared to the same periods in 2024. Selling, general and administrative expenses remained consistent for both the three and six months ended June 30, 2025, compared to the same periods in 2024. Depreciation and amortization expenses increased by $7 million and $8 million for the three and six months ended June 30, 2025, respectively, compared to the same periods in 2024.
The company also incurred restructuring costs of $32 million for the three months ended June 30, 2025, and $61 million for the six months ended June 30, 2025, as part of ongoing efforts to streamline its global operations and reduce overcapacity to adapt to changing market conditions and integrate acquisitions.
Furthermore, interest income decreased, primarily due to lower interest rates, while interest expenses increased during the three and six months ended June 30, 2025, compared to the same periods in 2024.
As a result of these announcements, the company's shares have moved 3.07% on the market, and are now trading at a price of $193.14. If you want to know more, read the company's complete 10-Q report here.
